SCHEMBL4707932

SCHEMBL4707932

CC(=O)c1c(-c2ccccc2)nn(C)c(=O)c1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 1.00
CSF1R P07333 1/20 1.00
FGFR1 P11362 1/20 1.00
FLT1 P17948 1/20 1.00
KDR P35968 1/20 1.00
CSNK1A1 P48729 1/20 1.00
GSK3A P49840 1/20 1.00
GSK3B P49841 1/20 1.00
CDK5 Q00535 1/20 1.00
PRKCQ Q04759 1/20 1.00
LRRK2 Q5S007 1/20 1.00
CLK4 Q9HAZ1 1/20 1.00
DYRK1B Q9Y463 1/20 1.00
ACVR1 Q04771 1/20 0.52
POLB P06746 1/20 0.52
TP53 P04637 3/20 0.52
LMNA P02545 1/20 0.52
ADRA1A P35348 3/20 0.52
ADRA1B P35368 3/20 0.52
ADRA1D P25100 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15656069 0.83 KDR (0.71) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL4708325 0.83 KDR (0.71) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL4708836 0.82 CSF1R (0.70) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL3032899 0.82 CSF1R (0.69) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL4707518 0.82 KDR (0.69) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL4705975 0.80 CSF1R (0.66) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL8888266 0.80 CSF1R (0.66) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL17295334 0.78 CSF1R (0.64) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL17290901 0.78 CSF1R (0.64) CDK8CSF1RFGFR1FLT1KDR
SCHEMBL27641378 0.78 CSF1R (0.63) CDK8CSF1RFGFR1FLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B CDK8 844/4885CSF1R 4118/4885FGFR1 2580/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B CDK8 844/4885CSF1R 4118/4885FGFR1 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.